Journal
LANCET
Volume 373, Issue 9680, Pages 2055-2066Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(09)60492-X
Keywords
-
Categories
Funding
- Medical Research Council [G0701075] Funding Source: researchfish
- Parkinson's UK [G-0907] Funding Source: researchfish
- Medical Research Council [G0701075] Funding Source: Medline
- Parkinson's UK [G-0907] Funding Source: Medline
- MRC [G0701075] Funding Source: UKRI
Ask authors/readers for more resources
Parkinson's disease is a common progressive bradykinetic disorder that can be accurately diagnosed. It is characterised by the presence of severe pars-compacta nigral-cell loss, and accumulation of aggregated alpha-synuclein in specific brain stem, spinal cord, and cortical regions. The main known risk factor is age. Susceptibility genes including a-synuclein, leucine rich repeat kinase 2 (LRRK-2), and glucocerebrosidase (GBA) have shown that genetic predisposition is another important causal factor. Dopamine replacement therapy considerably reduces motor handicap, and effective treatment of associated depression, pain, constipation, and nocturnal difficulties can improve quality of life. Embryonic stem cells and gene therapy are promising research therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available